View Future GrowthCytophage Technologies 過去の業績過去 基準チェック /06Cytophage Technologies は平均年間 41.1% の収益成長を遂げていますが、Biotechs 業界では年間 収益成長率 となっています。33.8% です。主要情報41.10%収益成長率48.79%EPS成長率Biotechs 業界の成長17.04%収益成長率n/a株主資本利益率-216.73%ネット・マージンn/a前回の決算情報30 Jun 2025最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Jan 21Cytophage Technologies Ltd. Announces Chief Financial Officer ChangesCytophage Technologies Ltd. announced the appointment of James Kinley, CPA CA, as Chief Financial Officer. Mr. Kinley is based in Winnipeg and brings extensive experience in the biotech industry, having served as a CFO to several publicly listed healthcare companies over the past 15 years, including his current engagement as CFO to Algernon Health Inc. He will work with management and the Board of Directors to ensure continued compliance with the Company's financial reporting obligations and the requirements of applicable securities regulators and the TSX Venture Exchange. As a fractional CFO, the Company will also be able to benefit from cost savings in the appointment of Mr. Kinley. Mr. Kinley replaces Julius Kalcevich who has been the Company’s CFO since July 2023. Mr. Kalcevich was brought on to take the Company public through a reverse takeover and lead several financing efforts. Mr. Kalcevich has agreed to assist with an orderly transition and will work closely with Mr. Kinley to support continuity of financial oversight, reporting, and public company compliance during the transition period. Mr. Kalcevich will remain available to the Company as an ad-hoc independent consultant.お知らせ • Nov 29Cytophage Technologies Ltd. announced that it has received CAD 1.2 million in fundingOn November 28, 2025, the company has closed the transaction. The company has issued 990,000 Units at a price of CAD 0.2 per unit for aggregate proceeds of CAD198,000. In connection with the closing, the Company has also agreed, subject to receiving Exchange approval, to pay finder’s fees of CAD4,200 in cash and to 21,000 broker warrants, on the same terms as the Warrants forming part of the Offering, to qualified non related parties. The closing of the Offering remains subject to all regulatory approvals from the TSX Venture Exchange.お知らせ • Oct 17Cytophage Technologies Ltd. announced that it expects to receive CAD 1.2 million in fundingCytophage Technologies Ltd. announced a non-brokered private placement of up to 6,000,000 units at CAD 0.20 per Unit , for gross proceeds of up to CAD 1,200,000. Each Unit consists of one common share of the Company and one half of a common share purchase warrant. Each whole Warrant entitles the holder thereof to purchase one additional Share at a price of CAD 0.40 per Warrant Share, for a period of 24 months from the date of issuance. The Company reserves the right to increase the size of the Offering by up to an additional CAD 600,000 through the sale of up to 3,000,000 additional Units. All securities issued under the Offering, including Warrant Shares issuable upon exercise of the warrants and finders warrant shares issuable upon exercise of the Finders Warrants, will be subject to a hold period expiring 4 months and 1 day after each applicable closing date, in accordance with the rules and policies of the TSX Venture Exchange and applicable Canadian securities laws. The Company may close the Offering in multiple tranches. With the pending regulatory approvals from the TSX Venture Exchange, the Company expects to close the Offering on or about November 6, 2025.お知らせ • Jun 11Cytophage Technologies Ltd. announced that it has received CAD 1.55 million in fundingOn June 10, 2025, Cytophage Technologies Ltd. closed the transaction. In connection with offering company paid pay finders' fees of CAD 27,545 in cash and issue 128,975 broker warrants. All securities issued are subject to a four-month hold period expiring Oct. 11, 2025.The company's directors and senior officers have collectively subscribed for 1,212,500 units for CAD 242,500, representing approximately 15.7 per cent of the total offering.お知らせ • May 14Cytophage Technologies Ltd. announced that it expects to receive CAD 1 million in fundingCytophage Technologies Ltd announced a non brokered private placement to issue 5,000,000 units at a price of CAD 0.2 per unit for aggregate gross proceeds of CAD 1,000,000 on May 14, 2025. Each unit consists of one common share of the company and one common share purchase warrant. Each Warrant entitles the holder thereof to purchase one additional common share of the company at a price of CAD 0.4 per warrant share for a period of 24 months from the date of issuance. The company has received commitments from its directors and officers to subscribe for approximately 1,000,000 units, for gross proceeds of approximately CAD 200,000. The company anticipates closing the offering in multiple tranches. Pending all regulatory approvals from the TSX Venture Exchange, the company expects to close the first tranche of the offering on or about May 22, 2025. The company may pay finder’s fees of up to 7% of gross proceeds raised and issue warrants, on the same terms as the Warrants forming part of the units, of up to 7% of the number of units sold to investors, to qualified non-related parties, in accordance with the policies of the exchange. All securities issued under the offering, including warrant shares issuable on exercise of the Warrants, will be subject to a hold period expiring 4 months and 1 day after issuance, in accordance with the rules and policies of the Exchange and applicable Canadian securities laws.お知らせ • Apr 30Cytophage Technologies Ltd., Annual General Meeting, Jun 25, 2025Cytophage Technologies Ltd., Annual General Meeting, Jun 25, 2025.収支内訳Cytophage Technologies の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:CPTC.F 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費30 Jun 250-54031 Mar 250-54031 Dec 240-84030 Sep 240-85030 Jun 240-85031 Mar 240-85031 Dec 230-540質の高い収益: CPTC.Fは現在利益が出ていません。利益率の向上: CPTC.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: CPTC.Fの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: CPTC.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: CPTC.Fは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。株主資本利益率高いROE: CPTC.Fは現在利益が出ていないため、自己資本利益率 ( -216.73% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/10/18 17:20終値2025/07/21 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cytophage Technologies Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 21Cytophage Technologies Ltd. Announces Chief Financial Officer ChangesCytophage Technologies Ltd. announced the appointment of James Kinley, CPA CA, as Chief Financial Officer. Mr. Kinley is based in Winnipeg and brings extensive experience in the biotech industry, having served as a CFO to several publicly listed healthcare companies over the past 15 years, including his current engagement as CFO to Algernon Health Inc. He will work with management and the Board of Directors to ensure continued compliance with the Company's financial reporting obligations and the requirements of applicable securities regulators and the TSX Venture Exchange. As a fractional CFO, the Company will also be able to benefit from cost savings in the appointment of Mr. Kinley. Mr. Kinley replaces Julius Kalcevich who has been the Company’s CFO since July 2023. Mr. Kalcevich was brought on to take the Company public through a reverse takeover and lead several financing efforts. Mr. Kalcevich has agreed to assist with an orderly transition and will work closely with Mr. Kinley to support continuity of financial oversight, reporting, and public company compliance during the transition period. Mr. Kalcevich will remain available to the Company as an ad-hoc independent consultant.
お知らせ • Nov 29Cytophage Technologies Ltd. announced that it has received CAD 1.2 million in fundingOn November 28, 2025, the company has closed the transaction. The company has issued 990,000 Units at a price of CAD 0.2 per unit for aggregate proceeds of CAD198,000. In connection with the closing, the Company has also agreed, subject to receiving Exchange approval, to pay finder’s fees of CAD4,200 in cash and to 21,000 broker warrants, on the same terms as the Warrants forming part of the Offering, to qualified non related parties. The closing of the Offering remains subject to all regulatory approvals from the TSX Venture Exchange.
お知らせ • Oct 17Cytophage Technologies Ltd. announced that it expects to receive CAD 1.2 million in fundingCytophage Technologies Ltd. announced a non-brokered private placement of up to 6,000,000 units at CAD 0.20 per Unit , for gross proceeds of up to CAD 1,200,000. Each Unit consists of one common share of the Company and one half of a common share purchase warrant. Each whole Warrant entitles the holder thereof to purchase one additional Share at a price of CAD 0.40 per Warrant Share, for a period of 24 months from the date of issuance. The Company reserves the right to increase the size of the Offering by up to an additional CAD 600,000 through the sale of up to 3,000,000 additional Units. All securities issued under the Offering, including Warrant Shares issuable upon exercise of the warrants and finders warrant shares issuable upon exercise of the Finders Warrants, will be subject to a hold period expiring 4 months and 1 day after each applicable closing date, in accordance with the rules and policies of the TSX Venture Exchange and applicable Canadian securities laws. The Company may close the Offering in multiple tranches. With the pending regulatory approvals from the TSX Venture Exchange, the Company expects to close the Offering on or about November 6, 2025.
お知らせ • Jun 11Cytophage Technologies Ltd. announced that it has received CAD 1.55 million in fundingOn June 10, 2025, Cytophage Technologies Ltd. closed the transaction. In connection with offering company paid pay finders' fees of CAD 27,545 in cash and issue 128,975 broker warrants. All securities issued are subject to a four-month hold period expiring Oct. 11, 2025.The company's directors and senior officers have collectively subscribed for 1,212,500 units for CAD 242,500, representing approximately 15.7 per cent of the total offering.
お知らせ • May 14Cytophage Technologies Ltd. announced that it expects to receive CAD 1 million in fundingCytophage Technologies Ltd announced a non brokered private placement to issue 5,000,000 units at a price of CAD 0.2 per unit for aggregate gross proceeds of CAD 1,000,000 on May 14, 2025. Each unit consists of one common share of the company and one common share purchase warrant. Each Warrant entitles the holder thereof to purchase one additional common share of the company at a price of CAD 0.4 per warrant share for a period of 24 months from the date of issuance. The company has received commitments from its directors and officers to subscribe for approximately 1,000,000 units, for gross proceeds of approximately CAD 200,000. The company anticipates closing the offering in multiple tranches. Pending all regulatory approvals from the TSX Venture Exchange, the company expects to close the first tranche of the offering on or about May 22, 2025. The company may pay finder’s fees of up to 7% of gross proceeds raised and issue warrants, on the same terms as the Warrants forming part of the units, of up to 7% of the number of units sold to investors, to qualified non-related parties, in accordance with the policies of the exchange. All securities issued under the offering, including warrant shares issuable on exercise of the Warrants, will be subject to a hold period expiring 4 months and 1 day after issuance, in accordance with the rules and policies of the Exchange and applicable Canadian securities laws.
お知らせ • Apr 30Cytophage Technologies Ltd., Annual General Meeting, Jun 25, 2025Cytophage Technologies Ltd., Annual General Meeting, Jun 25, 2025.